We Think UnicoCell Biomed (TWSE:6794) Can Easily Afford To Drive Business Growth
May 21
Taiwanese (TAIEX) Biotech Industry Analysis
UpdatedMay 29, 2024
DataAggregated Company Financials
Companies61
- 7D-0.7%
- 3M1.2%
- 1Y-9.0%
- YTD0.7%
Over the last 7 days, the Biotech industry has remained flat, although notably Sunmax Biotechnology gained 19%. As for the longer term, the industry has declined 11% in the last year. As for the next few years, earnings are expected to grow by 74% per annum.
Industry Valuation and Performance
Has the Taiwanese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 29 May 2024 | NT$491.7b | NT$21.9b | -NT$11,084,581,000.00 | 41.8x | -44.4x | 22.4x |
| Fri, 26 Apr 2024 | NT$436.0b | NT$21.1b | -NT$12,457,752,000.00 | 49.2x | -35x | 20.6x |
| Sun, 24 Mar 2024 | NT$432.7b | NT$20.9b | -NT$10,146,166,000.00 | 50.5x | -42.6x | 20.7x |
| Tue, 20 Feb 2024 | NT$445.3b | NT$19.9b | -NT$9,857,794,000.00 | 40.1x | -45.2x | 22.4x |
| Thu, 18 Jan 2024 | NT$447.0b | NT$19.8b | -NT$9,748,146,000.00 | 39.8x | -45.9x | 22.6x |
| Sat, 16 Dec 2023 | NT$474.2b | NT$19.9b | -NT$9,737,975,000.00 | 42.5x | -48.7x | 23.9x |
| Mon, 13 Nov 2023 | NT$471.4b | NT$18.5b | -NT$10,820,022,000.00 | 48.2x | -43.6x | 25.4x |
| Wed, 11 Oct 2023 | NT$472.2b | NT$18.3b | -NT$10,774,226,000.00 | 45.1x | -43.8x | 25.8x |
| Fri, 08 Sep 2023 | NT$483.6b | NT$18.3b | -NT$10,596,353,000.00 | 42.9x | -45.6x | 26.4x |
| Sun, 06 Aug 2023 | NT$466.7b | NT$18.6b | -NT$10,798,870,000.00 | 51.4x | -43.2x | 25.1x |
| Tue, 04 Jul 2023 | NT$486.6b | NT$18.7b | -NT$10,709,428,000.00 | 44.1x | -45.4x | 26.1x |
| Thu, 01 Jun 2023 | NT$496.9b | NT$18.9b | -NT$10,023,645,000.00 | 41.6x | -49.6x | 26.3x |
| Sat, 29 Apr 2023 | NT$515.7b | NT$18.5b | -NT$9,925,325,000.00 | 44.1x | -52x | 27.9x |
| Mon, 27 Mar 2023 | NT$504.9b | NT$20.5b | -NT$9,016,573,000.00 | 37.3x | -56x | 24.7x |
| Wed, 22 Feb 2023 | NT$524.4b | NT$21.8b | -NT$7,840,926,000.00 | 38x | -66.9x | 24x |
| Fri, 20 Jan 2023 | NT$494.2b | NT$21.8b | -NT$7,778,690,000.00 | 36.2x | -63.5x | 22.7x |
| Sun, 18 Dec 2022 | NT$512.6b | NT$21.8b | -NT$7,522,211,000.00 | 37.1x | -68.1x | 23.5x |
| Tue, 15 Nov 2022 | NT$495.2b | NT$23.1b | -NT$6,774,948,000.00 | 33.1x | -73.1x | 21.5x |
| Thu, 13 Oct 2022 | NT$480.5b | NT$23.1b | -NT$6,633,590,000.00 | 35x | -72.4x | 20.8x |
| Sat, 10 Sep 2022 | NT$630.6b | NT$23.1b | -NT$6,633,590,000.00 | 44.6x | -95.1x | 27.3x |
| Mon, 08 Aug 2022 | NT$560.6b | NT$22.6b | -NT$5,727,813,000.00 | 32.8x | -97.9x | 24.9x |
| Wed, 06 Jul 2022 | NT$502.4b | NT$22.5b | -NT$5,642,821,000.00 | 29.9x | -89x | 22.3x |
| Fri, 03 Jun 2022 | NT$506.4b | NT$22.5b | -NT$5,642,821,000.00 | 31.9x | -89.7x | 22.5x |
| Sun, 01 May 2022 | NT$529.2b | NT$21.4b | -NT$5,787,788,000.00 | 44.4x | -91.4x | 24.7x |
| Tue, 29 Mar 2022 | NT$518.3b | NT$19.6b | -NT$5,068,875,000.00 | 28.6x | -102.3x | 26.5x |
| Thu, 24 Feb 2022 | NT$474.3b | NT$17.9b | -NT$5,564,340,000.00 | 24.9x | -85.2x | 26.5x |
| Sat, 22 Jan 2022 | NT$428.1b | NT$17.9b | -NT$5,532,702,000.00 | 24.3x | -77.4x | 23.9x |
| Mon, 20 Dec 2021 | NT$462.4b | NT$17.9b | -NT$5,579,296,000.00 | 26.5x | -82.9x | 25.8x |
| Wed, 17 Nov 2021 | NT$354.7b | NT$16.9b | -NT$6,474,311,000.00 | 22x | -54.8x | 20.9x |
| Fri, 15 Oct 2021 | NT$341.8b | NT$15.4b | -NT$7,624,179,000.00 | 19.6x | -44.8x | 22.2x |
| Sun, 12 Sep 2021 | NT$385.5b | NT$15.4b | -NT$7,624,179,000.00 | 22x | -50.6x | 25.1x |
| Tue, 10 Aug 2021 | NT$395.1b | NT$15.4b | -NT$7,624,179,000.00 | 21.1x | -51.8x | 25.7x |
Price to Earnings Ratio
-48x
Current Industry PE
- Investors are relatively neutral on the Taiwanese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 24.3x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 17% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Taiwanese Healthcare industry?
| TW Market | 2.89% | |
| Healthcare | -0.91% | |
| Biotech | -0.68% | |
| Biotech | -0.68% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 4728 Sunmax Biotechnology | NT$293.50 | 18.6% +NT$2.5b | 27.9% | PE23.7x | |
| 6794 UnicoCell Biomed | NT$84.00 | 13.7% +NT$562.4m | -3.3% | PS199.9x | |
| 3176 Medigen Biotechnology | NT$43.30 | 3.7% +NT$215.8m | 29.8% | PS4.8x | |
| 4147 TaiMed Biologics | NT$88.70 | 0.8% +NT$191.1m | -19.0% | PS40.4x | |
| 6652 Eusol BiotechLtd | NT$9.39 | 14.8% +NT$165.8m | -15.8% | PB3.2x |